linvemastat (FP-020) / Foresee Pharma - LARVOL DELTA

Foresee Pharmaceuticals Announces a Keynote Oral Presentation and Participation at the 2025 American Thoracic Society International Conference (PRNewswire) - "Foresee Pharmaceuticals...that it will actively participate in and Toby Maher, M.D., will deliver a keynote presentation titled "SyMMPonia: A Phase 2 Study of Linvemastat (FP-020) in Uncontrolled Asthma" at the Innovation Theater on May 18, 2025. The session will highlight the design and objectives of the multinational syMMPonia Study, a pivotal clinical trial evaluating the efficacy of Linvemastat (FP-020), a novel Matrix Metalloproteinase-12 (MMP-12) inhibitor, in patients with uncontrolled asthma."

Clinical protocol • Asthma

SyMMPonia: a Phase 2 Study of Linvemastat (FP-020) in Uncontrolled Asthma (ATS 2025) - "Sponsored by Foresee Pharmaceuticals Description Speaker: Toby Maher, M.D. Program Title: A Multinational Phase 2, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effect of FP-020 (Matrix Metalloproteinase-12 inhibitor) in Patients with Uncontrolled Asthma on Inhaled Corticosteroids (ICS) with Long-Acting Beta Agonist (LABA) as a Standard of Care (syMMPonia Study)"

P2 data • Asthma • Immunology • Respiratory Diseases

Safety, Tolerability, and Pharmacokinetics, of Single and Multiple Ascending Doses of FP-020 in Healthy Adult Volunteers (clinicaltrials.gov) - P1 | N=64 | Completed | Sponsor: Foresee Pharmaceuticals Co., Ltd. | Recruiting ➔ Completed

Trial completion

Safety, Tolerability, and Pharmacokinetics, of Single and Multiple Ascending Doses of FP-020 in Healthy Adult Volunteers (clinicaltrials.gov) - P1 | N=74 | Recruiting | Sponsor: Foresee Pharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting | Trial completion date: Jan 2025 ➔ Oct 2024

Enrollment open • Trial completion date

Foresee Pharmaceuticals Announces First Subject Dosed in its First-in-Human Clinical Trial of FP-020 (PRNewswire) - "Foresee Pharmaceuticals...announced that the first subject has been dosed in its Phase 1 clinical trial of FP-020 in Australia...The Phase 1 clinical trial is a randomized, double-blind, placebo-controlled, single-center, single, and multiple ascending oral dose study to evaluate the safety, tolerability, and pharmacokinetics of FP-020 in healthy volunteers. Up to 74 subjects will be enrolled at a site in Australia...'The initiation of this Phase 1 trial underscores our commitment to advancing innovative therapies to benefit patients with severe asthma and COPD.'"

Trial status • Asthma • Chronic Obstructive Pulmonary Disease

Safety, Tolerability, and Pharmacokinetics, of Single and Multiple Ascending Doses of FP-020 in Healthy Adult Volunteers (clinicaltrials.gov) - P1 | N=74 | Not yet recruiting | Sponsor: Foresee Pharmaceuticals Co., Ltd.

New P1 trial